Literature DB >> 17142714

Percutaneous protective coil occlusion of the proximal inferior mesenteric artery before N-butyl cyanoacrylate embolization of type II endoleaks after endovascular repair of abdominal aortic aneurysms.

Christine P Chao1, Ricardo Paz-Fumagalli, Eric M Walser, J Mark McKinney, Andrew H Stockland, Jürgen Falkensammer, Albert G Hakaim, W Andrew Oldenburg.   

Abstract

Bowel ischemia can complicate treatment of type II endoleak with liquid or semiliquid agents such as n-butyl cyanoacrylate (NBCA) if nontarget embolization of the inferior mesenteric artery (IMA) occurs. The current report describes four cases of type II endoleak in which the IMA was the main outflow vessel and was prophylactically occluded with embolization coils before NBCA injection into the endoleak nidus. The purpose was to prevent unintentional embolization of the NBCA into IMA branches. If feasible, protective IMA coil occlusion should be considered in type II endoleaks with IMA outflow in cases of NBCA embolization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142714     DOI: 10.1097/01.RVI.0000242188.04050.6D

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  2 in total

1.  Use of n-butyl cyanoacrylate in abdominal and pelvic embolotherapy: indications and techniques, complications, and their management.

Authors:  Mikako Enokizono; Ichiro Sakamoto; Hideyuki Hayashi; Eijun Sueyoshi; Masataka Uetani
Journal:  Jpn J Radiol       Date:  2012-02-28       Impact factor: 2.374

2.  Guidelines for the use of NBCA in vascular embolization devised by the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (CGJSIR), 2012 edition.

Authors:  Yoshito Takeuchi; Hiroyuki Morishita; Yozo Sato; Shingo Hamaguchi; Noriaki Sakamoto; Hiroyuki Tokue; Takafumi Yonemitsu; Kenji Murakami; Hiroyasu Fujiwara; Keitaro Sofue; Toshi Abe; Hideyuki Higashihara; Yasuo Nakajima; Morio Sato
Journal:  Jpn J Radiol       Date:  2014-06-03       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.